Johnson & Johnson's CARVYKTI Shows 50% Five-Year Remission in Early-Line Multiple Myeloma
Event summary
- 50% of patients (10/20) in early-line relapsed/refractory multiple myeloma achieved five-year progression-free survival with a single CARVYKTI infusion.
- Median progression-free survival was 60.5 months, with a five-year overall survival rate of 69.2%.
- Results presented at the 2026 International Myeloma Society (IMS) Annual Meeting.
- CARVYKTI's safety profile remained consistent with no new CAR T-cell-related neurotoxicity reported.
- One patient developed acute myeloid leukemia, and two deaths occurred due to progressive disease and new cancer.
The big picture
Johnson & Johnson's CARVYKTI continues to demonstrate strong efficacy in earlier lines of multiple myeloma treatment, reinforcing the shift towards earlier intervention with cellular therapies. The results support the broader industry trend of moving towards curative approaches in oncology, particularly for blood cancers. With over 13,000 patients treated globally, CARVYKTI's expanding label and clinical success position Johnson & Johnson as a leader in the evolving multiple myeloma treatment landscape.
What we're watching
- Curative Potential
- Whether CARVYKTI can achieve curative potential in a broader patient population beyond early-line relapsed/refractory multiple myeloma.
- Regulatory Expansion
- The pace at which CARVYKTI gains approvals in additional markets and for earlier lines of therapy.
- Competitive Dynamics
- How Johnson & Johnson's CARVYKTI will compete with emerging BCMA-targeting therapies and other cellular immunotherapies in the multiple myeloma space.
Related topics